IRWD Company Profile and Key Details
Ironwood Pharmaceuticals
Price Chart
Stock Price Today
Ironwood Pharmaceuticals, Inc. (IRWD) stock declined over -0.57%, trading at $4.35 on NASDAQ, down from the previous close of $4.37. The stock opened at $4.43, fluctuating between $4.24 and $4.44 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 14, 2026 | 3.96 | 4.31 | 3.95 | 4.04 | 3.56M |
| Apr 13, 2026 | 3.58 | 3.68 | 3.53 | 3.65 | 865.52K |
| Apr 10, 2026 | 3.60 | 3.65 | 3.51 | 3.63 | 1.22M |
| Apr 09, 2026 | 3.50 | 3.62 | 3.41 | 3.60 | 1.05M |
| Apr 08, 2026 | 3.54 | 3.60 | 3.46 | 3.51 | 1.54M |
| Apr 07, 2026 | 3.49 | 3.50 | 3.34 | 3.46 | 1.09M |
| Apr 06, 2026 | 3.51 | 3.65 | 3.49 | 3.53 | 1.28M |
| Apr 02, 2026 | 3.76 | 3.77 | 3.52 | 3.54 | 1.89M |
| Apr 01, 2026 | 3.59 | 3.93 | 3.56 | 3.90 | 2.68M |
| Mar 31, 2026 | 3.27 | 3.60 | 3.27 | 3.51 | 3.16M |
| Mar 30, 2026 | 3.06 | 3.34 | 3.05 | 3.23 | 1.91M |
| Mar 27, 2026 | 3.10 | 3.20 | 3.03 | 3.06 | 1.35M |
| Mar 25, 2026 | 3.09 | 3.26 | 3.09 | 3.19 | 1.12M |
| Mar 24, 2026 | 3.26 | 3.26 | 3.04 | 3.04 | 1.69M |
| Mar 23, 2026 | 3.18 | 3.40 | 3.18 | 3.29 | 2.82M |
| Mar 20, 2026 | 3.20 | 3.25 | 3.02 | 3.04 | 14.23M |
| Mar 19, 2026 | 3.14 | 3.26 | 3.06 | 3.23 | 3.4M |
| Mar 18, 2026 | 3.22 | 3.31 | 3.13 | 3.17 | 3.24M |
| Mar 17, 2026 | 3.37 | 3.52 | 3.05 | 3.25 | 10.41M |
| Mar 16, 2026 | 3.44 | 3.50 | 3.33 | 3.37 | 1.68M |
Contact Details
About Company
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Company Information
| Employees | 253 |
| Beta | 0.17 |
| Sales or Revenue | $442.74M |
| 5Y Sales Change% | 0.254% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
Financial & Profitability Overview
On valuation metrics, Ironwood Pharmaceuticals trades at a P/E of 26.91, P/S of 2.19 and P/B of -2.47. The current ratio is 1.13 and quick ratio is 1.13. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 19.69 days. Debt-to-equity is -2.28, supported by a cash flow-to-debt ratio of 0.21.
Quarterly Financial Highlights
The company ended the quarter with $92.15M in cash and short-term investments, a total debt of $715.54M, and net debt of $623.38M. Total assets were $471.07M, with equity of - $346.30M. Financials further reflected stability, with operating cash flow of $183.43M, free cash flow of $183.15M, and capital expenditures of - $273.00K.
Frequently Asked Questions
Executive Chairman
Mr. Marcel Moulaison
Vice President of Technical Operations
Mr. Jason Rickard
Senior Vice President & Chief Operating Officer
Dr. Michael Shetzline M.D., Ph.D.
Chief Medical Officer, Senior Vice President and Head of Research & Drug Devel.
Mr. Thomas A. McCourt
Chief Executive Officer & Director
Mr. Mike Nanfito
Vice President of Sales & Sales Excellence
Mr. Ronald Silver
Corporation Controller & Principal Accounting Officer
Ms. Beth Calitri
Head of Corporation Communications & Media Relations
Mr. John Minardo
Senior Vice President, Chief Legal Officer & Sec.
Greg Martini
Vice President of Strategic Fin. & Investor Relations
Mr. Sravan Kumar Emany
Senior Vice President, Principal Financial Officer & Chief Financial Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep